V M Asensio-Sánchez. Show Affiliations »
Abstract
Entities: Chemical
Mesh: See more » Angiogenesis Inhibitors/chemistryAngiogenesis Inhibitors/pharmacokineticsAngiogenesis Inhibitors/pharmacologyAntibodies, Monoclonal/chemistryAntibodies, Monoclonal/immunologyAntibodies, Monoclonal/pharmacokineticsAntibodies, Monoclonal/pharmacologyAntibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, HumanizedAntibody SpecificityBevacizumabGlycosylationHumansImmunoglobulin Fab Fragments/immunologyMacular Degeneration/drug therapyProtein Processing, Post-TranslationalRanibizumabStructure-Activity RelationshipVascular Endothelial Growth Factor A/antagonists & inhibitorsVascular Endothelial Growth Factor A/immunology
Substances: See more » Angiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedImmunoglobulin Fab FragmentsVEGFA protein, humanVascular Endothelial Growth Factor ABevacizumabRanibizumab
Year: 2009 PMID: 19809922 DOI: 10.4321/s0365-66912009000900002
Source DB: PubMed Journal: Arch Soc Esp Oftalmol ISSN: 0365-6691